<SEC-DOCUMENT>0001437749-16-037478.txt : 20160815
<SEC-HEADER>0001437749-16-037478.hdr.sgml : 20160815
<ACCEPTANCE-DATETIME>20160815162000
ACCESSION NUMBER:		0001437749-16-037478
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20160815
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20160815
DATE AS OF CHANGE:		20160815

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Diffusion Pharmaceuticals Inc.
		CENTRAL INDEX KEY:			0001053691
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				300645032
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-24477
		FILM NUMBER:		161833007

	BUSINESS ADDRESS:	
		STREET 1:		2020 AVON COURT
		STREET 2:		SUITE 4
		CITY:			CHARLOTTESVILLE
		STATE:			VA
		ZIP:			22902
		BUSINESS PHONE:		(434) 220-0718

	MAIL ADDRESS:	
		STREET 1:		2020 AVON COURT
		STREET 2:		SUITE 4
		CITY:			CHARLOTTESVILLE
		STATE:			VA
		ZIP:			22902

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RestorGenex Corp
		DATE OF NAME CHANGE:	20140307

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Stratus Media Group, Inc
		DATE OF NAME CHANGE:	20080722

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	FERIS INTERNATIONAL, INC.
		DATE OF NAME CHANGE:	20080228
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>dffn20160812_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD><TITLE>dffn20160812_8k.htm</TITLE>
<!-- Created by RDG HTML Converter -->
</HEAD>
<BODY style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 10px; MARGIN-RIGHT: 10px">
<HR style="MARGIN-BOTTOM: 2px; BORDER-TOP: medium none; HEIGHT: 3px; BORDER-RIGHT: medium none; WIDTH: 100%; BORDER-BOTTOM: medium none; COLOR: #000000; BORDER-LEFT: medium none; MARGIN-TOP: 0px; BACKGROUND-COLOR: #000000">

<HR style="BORDER-TOP: medium none; HEIGHT: 1px; BORDER-RIGHT: medium none; WIDTH: 100%; BORDER-BOTTOM: medium none; POSITION: relative; COLOR: #000000; BORDER-LEFT: medium none; MARGIN-TOP: 0px; TOP: 0px; BACKGROUND-COLOR: #000000">

<P id=PARA1 style="TEXT-ALIGN: right; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA2 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-TRANSFORM: uppercase"><B>UNITED STATES</B></FONT></P>
<P id=PARA3 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-TRANSFORM: uppercase"><B>SECURITIES AND EXCHANGE COMMISSION</B></FONT></P>
<P id=PARA4 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Washington, D.C. 20549</B></FONT></P>
<P id=PARA5 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-TRANSFORM: uppercase">__________________</FONT></P>
<P id=PARA6 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA7 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-TRANSFORM: uppercase"><B>FORM 8-K</B></FONT></P>
<P id=PARA8 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA9 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-TRANSFORM: uppercase"><B>CURRENT REPORT</B></FONT></P>
<P id=PARA10 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Pursuant to Section 13 or 15(d) of</B></FONT></P>
<P id=PARA11 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>the Securities Exchange Act of 1934</B></FONT></P>
<P id=PARA12 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-TRANSFORM: uppercase">__________________</FONT></P>
<P id=PARA13 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA14 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Date of Report (Date of earliest event reported): August 15, 2016</B></FONT></P>
<P id=PARA15 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-TRANSFORM: uppercase">___________________</FONT></P>
<P id=PARA16 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA17 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman, Times, serif"><B>DIFFUSION PHARMACEUTICALS INC.</B></FONT></P>
<P id=PARA18 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">(Exact name of registrant as specified in its charter)</FONT></P>
<P id=PARA19 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA20 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=TBL29  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 33.2%; VERTICAL-ALIGN: top">
<P id=PARA21 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Delaware</B></FONT></P></TD>
<TD style="WIDTH: 33.4%; VERTICAL-ALIGN: top">
<P id=PARA22 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>000-24477</B></FONT></P></TD>
<TD style="WIDTH: 33.4%; VERTICAL-ALIGN: top">
<P id=PARA23 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>30-0645032</B></FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 33.2%; VERTICAL-ALIGN: top">
<P id=PARA24 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">(State or other jurisdiction of</FONT></P>
<P style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">incorporation)</FONT></P></TD>
<TD style="WIDTH: 33.4%; VERTICAL-ALIGN: top">
<P id=PARA25 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">(Commission File</FONT></P>
<P id=PARA26 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Number)</FONT></P></TD>
<TD style="WIDTH: 33.4%; VERTICAL-ALIGN: top">
<P id=PARA27 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">(I.R.S. Employer</FONT></P>
<P id=PARA28 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Identification No.)</FONT></P></TD></TR></TABLE>
<P id=PARA30 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.5pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA31 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.5pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=TBL38  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="WIDTH: 50%; VERTICAL-ALIGN: top">
<P id=PARA32 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>2020 Avon Court, #4</B></FONT></P>
<P id=PARA33 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Charlottesville, Virginia</B></FONT></P></TD>
<TD style="WIDTH: 50%; VERTICAL-ALIGN: top">
<P id=PARA34 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>&nbsp;</B></FONT></P>
<P id=PARA35 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>22902</B></FONT></P></TD></TR>
<TR>
<TD style="WIDTH: 50%; VERTICAL-ALIGN: top">
<P id=PARA36 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">(Address of principal executive offices)</FONT></P></TD>
<TD style="WIDTH: 50%; VERTICAL-ALIGN: top">
<P id=PARA37 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">(Zip Code)</FONT></P></TD></TR></TABLE>
<P id=PARA39 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-TRANSFORM: uppercase">&nbsp;</FONT></P>
<P id=PARA40 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>(434) 220-0718</B></FONT></P>
<P id=PARA41 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">(Registrant&#8217;s telephone number, including area code)</FONT></P>
<P id=PARA42 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA43 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Not applicable</B></FONT></P>
<P id=PARA44 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">(Former name or former address, if changed since last report)</FONT></P>
<P id=PARA45 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA46 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</FONT></P>
<P id=PARA47 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA48 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></P>
<P id=PARA49 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA50 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></P>
<P id=PARA51 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA52 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></P>
<P id=PARA53 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA54 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></P>
<P style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25">&nbsp;</P>
<HR style="MARGIN-BOTTOM: 2px; BORDER-TOP: medium none; HEIGHT: 1px; BORDER-RIGHT: medium none; WIDTH: 100%; BORDER-BOTTOM: medium none; COLOR: #000000; BORDER-LEFT: medium none; MARGIN-TOP: 0px; BACKGROUND-COLOR: #000000">

<HR style="MARGIN-BOTTOM: 0px; BORDER-TOP: medium none; HEIGHT: 3px; BORDER-RIGHT: medium none; WIDTH: 100%; BORDER-BOTTOM: medium none; POSITION: relative; COLOR: #000000; BORDER-LEFT: medium none; MARGIN-TOP: 0px; TOP: 0px; BACKGROUND-COLOR: #000000">

<P id=PARA111.1 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<DIV id=PGBK111  style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR111  style="WIDTH: 100%; TEXT-ALIGN: center">&nbsp;</DIV>
<DIV id=PGNUM111  style="FONT-SIZE: 10pt; WIDTH: 100%; TEXT-ALIGN: center">&nbsp;</DIV>
<HR style="HEIGHT: 2px; WIDTH: 100%; PAGE-BREAK-AFTER: always; COLOR: #000000" noShade>

<DIV id=PGHDR111  style="WIDTH: 100%; TEXT-ALIGN: left">&nbsp;</DIV></DIV>
<P id=PARA111.2 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA57 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Item 2.02 &#8211; Results of Operations and Financial Condition</B></FONT></P>
<P id=PARA58 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA59 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">On August 15, 2016, Diffusion Pharmaceuticals Inc. (the &#8220;Company&#8221;) issued a press release announcing its financial results for its second quarter ended June 30, 2016. A copy of that press release and the attached financial schedules are attached as Exhibit&nbsp;99.1 to this report and incorporated herein by reference.</FONT></P>
<P id=PARA60 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA61 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The information in this report (including Exhibit&nbsp;99.1) is being furnished pursuant to Item 2.02 and shall not be deemed to be &#8220;filed&#8221; for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act.</FONT></P>
<P id=PARA62 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA63 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Item&nbsp;9.01&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Financial Statements and Exhibits </B></FONT></P>
<P id=PARA65 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA64 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exhibits. </FONT></P>
<P id=PARA66 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=TBL72  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD style="VERTICAL-ALIGN: middle" width=120>&nbsp; </TD>
<TD style="VERTICAL-ALIGN: bottom" width=38>&nbsp; </TD>
<TD style="VERTICAL-ALIGN: middle" width=1011>&nbsp; </TD></TR>
<TR>
<TD style="VERTICAL-ALIGN: bottom" width=120>
<P id=PARA67 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><U><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Exhibit&nbsp;Number &nbsp; </FONT></U></P></TD>
<TD style="VERTICAL-ALIGN: bottom" width=38>
<P id=PARA68 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;&nbsp;</FONT></P></TD>
<TD style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid" width=1011>
<P id=PARA69 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Description</FONT></P></TD></TR>
<TR>
<TD style="VERTICAL-ALIGN: top" width=120>
<P id=PARA70 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">99.1</FONT></P></TD>
<TD style="VERTICAL-ALIGN: bottom" width=38>&nbsp; </TD>
<TD style="VERTICAL-ALIGN: top" width=1011>
<P id=PARA71 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Press release dated August 15, 2016, announcing financial results for the second quarter ended June 30, 2016.</FONT></P></TD></TR></TABLE>
<P id=PARA73.1 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<DIV id=PGBK73  style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR73  style="WIDTH: 100%; TEXT-ALIGN: center">&nbsp;</DIV>
<DIV id=PGNUM73  style="FONT-SIZE: 10pt; WIDTH: 100%; TEXT-ALIGN: center">&nbsp;</DIV>
<HR style="HEIGHT: 2px; WIDTH: 100%; PAGE-BREAK-AFTER: always; COLOR: #000000" noShade>

<DIV id=PGHDR73  style="WIDTH: 100%; TEXT-ALIGN: left">&nbsp;</DIV></DIV>
<P id=PARA73.2 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA75 style="TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; TEXT-TRANSFORM: uppercase"><B>SIGNATURES</B></FONT></P>
<P id=PARA76 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA77 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</FONT></P>
<P id=PARA78 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE id=TBL112  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0 border=0>

<TR>
<TD vAlign=top width="50%">
<P id=PARA112.1 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Dated: August 15, 2016</FONT></P></TD>
<TD vAlign=top width="38%" colSpan=2>
<P id=PARA112.2 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><B>DIFFUSION PHARMACEUTICALS INC.</B></FONT></P></TD>
<TD vAlign=top width="12%">
<P id=PARA112.3 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P></TD></TR>
<TR>
<TD vAlign=top width="50%">
<P id=PARA112.4 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P></TD>
<TD vAlign=top width="3%">
<P id=PARA112.5 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P></TD>
<TD vAlign=top width="35%">
<P id=PARA112.6 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P></TD>
<TD vAlign=top width="12%">
<P id=PARA112.7 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P></TD></TR>
<TR>
<TD vAlign=top width="50%">
<P id=PARA112.8 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P></TD>
<TD vAlign=top width="3%">
<P id=PARA112.9 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P></TD>
<TD vAlign=bottom width="35%" noWrap align=left>
<P id=PARA112.10 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P></TD>
<TD vAlign=top width="12%">
<P id=PARA112.11 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P></TD></TR>
<TR>
<TD style="TEXT-ALIGN: left" vAlign=top width="50%" align=left>
<P id=PARA112.12 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P></TD>
<TD style="TEXT-ALIGN: left" vAlign=top width="3%">
<P id=PARA112.13 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">By: </FONT></P></TD>
<TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=top width="35%" noWrap align=left>
<P id=PARA112.14 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;&nbsp; &nbsp; /s/&nbsp;David G. Kalergis&nbsp;</FONT></P></TD>
<TD vAlign=top width="12%">
<P id=PARA112.15 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P></TD></TR>
<TR>
<TD vAlign=top width="50%">
<P id=PARA112.16 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P></TD>
<TD vAlign=top colSpan=2>
<P id=PARA112.17 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px">Name:&nbsp;&nbsp;&nbsp; David G. Kalergis</P></TD>
<TD vAlign=top width="12%">
<P id=PARA112.19 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P></TD></TR>
<TR>
<TD vAlign=top width="50%">
<P id=PARA112.20 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P></TD>
<TD vAlign=top colSpan=2>
<P id=PARA112.21 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px">Title:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chief Executive Officer</P></TD>
<TD vAlign=top width="12%">
<P id=PARA112.23 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P></TD></TR></TABLE>
<P id=PARA79 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25">&nbsp;</P></BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML><HEAD><TITLE>ex99-1.htm</TITLE>
<!-- Created by RDG HTML Converter -->
</HEAD>
<BODY style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; MARGIN-LEFT: 10px; MARGIN-RIGHT: 10px">
<P id=PARA52 style="MARGIN-BOTTOM: 0px; TEXT-ALIGN: right; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Exhibit 99.1</B></FONT></P>
<P id=PARA53 style="MARGIN-BOTTOM: 0px; TEXT-ALIGN: left; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<TABLE  style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px" cellSpacing=0 cellPadding=0>

<TR>
<TD style="WIDTH: 100%">
<P id=PARA54 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt">&nbsp;<IMG src="a1.jpg" width=150 height=46></P></TD></TR></TABLE>
<P id=PARA1 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA2 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA3 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>FOR IMMEDIATE RELEASE</B></FONT></P>
<P id=PARA4 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>OTCQX: DFFN&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></P>
<P id=PARA6 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA7 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>&nbsp;</B></FONT></P>
<P id=PARA8 style="TEXT-ALIGN: center; MARGIN: 0pt 0pt 0pt 173.9pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -162.25pt"><FONT style="FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Diffusion Pharmaceuticals Provides Corporate Highlights and Reports</B></FONT></P>
<P id=PARA9 style="TEXT-ALIGN: center; MARGIN: 0pt 0pt 0pt 173.9pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -162.25pt"><FONT style="FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Financial Second Quarter 2016 Results</B></FONT></P>
<P id=PARA10 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>&nbsp;</B></FONT></P>
<P id=PARA11 style="TEXT-ALIGN: justify; MARGIN: 0pt 5.4pt 0pt 5pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Charlottesville, Virginia </B><B>(August 15</B><B>, </B><B>2016)</B> - Diffusion Pharmaceuticals Inc. (OTCQX: DFFN), a clinical stage biotechnology company focused on the development of novel small molecule therapeutics for cancer and other hypoxia-related diseases, today reported financial results for the three months ended June 30, 2016 and provided an overview of recent corporate highlights. The results will be filed shortly on the Quarterly Report on Form 10-Q with the SEC.</FONT></P>
<P id=PARA12 style="TEXT-ALIGN: justify; MARGIN: 0pt 5.4pt 0pt 5pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA13 style="TEXT-ALIGN: justify; MARGIN: 0pt 5.4pt 0pt 5pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">David Kalergis, Chairman and Chief Executive Officer, stated, &#8220;I am very excited about the progress that we have been making in advancing trans sodium crocetinate (TSC). The recently expanded patent estate of TSC demonstrates its broad applicability across multiple hypoxia driven indications impacting human health. In the near term, we plan to continue to expand the clinical development pipeline for TSC to include both glioblastoma (GBM) and pancreatic cancer. Also, we recently welcomed Isaac Blech, an experienced biotechnology entrepreneur and investor, to our Board of Directors as Vice Chairman.&#8221; </FONT></P>
<P id=PARA14 style="TEXT-ALIGN: justify; MARGIN: 0pt 5.4pt 0pt 5pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA15 style="TEXT-ALIGN: justify; MARGIN: 0pt 5.4pt 0pt 5pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Corporate Highlights</B></FONT></P>
<P id=PARA16 style="TEXT-ALIGN: justify; MARGIN: 0pt 5.55pt 0pt 6.75pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -0.25pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA17 style="TEXT-ALIGN: justify; MARGIN: 0pt 5.4pt 0pt 5pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In August 2016, Mr. Isaac Blech joined Diffusion&#8217;s Board of Directors as Vice Chairman. With over 35 years of biotech industry expertise, Mr. Blech has founded and served on the boards of a number of companies including Celgene Corporation, Nova Pharmaceutical Corporation, Pathogenesis Corporation, and Genetics Systems Corporation. </FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Among the other boards Mr. Blech currently serves on are Cerecor, Inc., a CNS company, ContraFect Corporation, an infectious disease company, Medgenics, Inc., a biotechnology company, and Edge Therapeutics, Inc., a company that treats life-threatening neurological conditions.</FONT></P>
<P id=PARA18 style="TEXT-ALIGN: justify; MARGIN: 0pt 5.4pt 0pt 5pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA19 style="TEXT-ALIGN: justify; MARGIN: 0pt 5.4pt 0pt 5pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In July 2016, the Company&#8217;s abstract related to medical emergency indications for its lead clinical stage drug candidate TSC has been accepted for presentation at the American College of Emergency Physicians (ACEP) Research Forum being held October 16 &#8211; 18, 2016 in Las Vegas. The acceptance of the abstract highlights the potential broad applicability of TSC as a life-saving intervention to reverse hypoxia in many medical emergencies, including hemorrhagic shock, myocardial infarction, and stroke.</FONT></P>
<P id=PARA20 style="TEXT-ALIGN: justify; MARGIN: 0pt 5.4pt 0pt 5pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA21 style="TEXT-ALIGN: justify; MARGIN: 0pt 5.4pt 0pt 5pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In June 2016, the Company&#8217;s U.S. patent application, entitled &#8220;Bipolar Trans Carotenoid Salts and Their Uses,&#8221; was allowed by the United States Patent and Trademark Office. This application, which is expected to issue in the second half of 2016, expands coverage of the therapeutic use TSC and other related compounds to five hypoxia-related conditions including congestive heart failure, chronic renal failure, acute lung injury, chronic obstructive pulmonary disease, and respiratory distress syndrome.</FONT></P>
<P id=PARA22 style="TEXT-ALIGN: justify; MARGIN: 0pt 5.4pt 0pt 5pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>&nbsp;</B></FONT></P>
<P id=PARA23 style="TEXT-ALIGN: justify; MARGIN: 0pt 5.4pt 0pt 5pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Three Months Ended June 30, 2016 Financial Results</B></FONT></P>
<P id=PARA24 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA25 style="TEXT-ALIGN: justify; MARGIN: 0pt 5.4pt 0pt 5pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Research and development expenses were $1.4 million for the three months ended June 30, 2016, compared to $0.9 million for the three months ended June 30, 2015. This increase was primarily a result of an increase in GBM program-related drug expenditures and expenses related to the TSC pancreatic cancer program.</FONT></P>
<P id=PARA55.1 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<DIV id=PGBK55  style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR55  style="WIDTH: 100%; TEXT-ALIGN: left"><IMG src="a2.jpg" width=100 height=61>&nbsp;</DIV>
<DIV id=PGNUM55  style="FONT-SIZE: 10pt; WIDTH: 100%; TEXT-ALIGN: left">&nbsp;</DIV>
<HR style="HEIGHT: 2px; WIDTH: 100%; PAGE-BREAK-AFTER: always; COLOR: #000000" noShade>

<DIV id=PGHDR55  style="WIDTH: 100%; TEXT-ALIGN: left">&nbsp;</DIV></DIV>
<P id=PARA55.2 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA27 style="TEXT-ALIGN: justify; MARGIN: 0pt 5.4pt 0pt 5pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">General and administrative expenses were $2.3 million for the three months ended June 30, 2016, compared to $0.3 million for the three months ended June 30, 2015. The increase was driven by a non-cash expense of $0.9 million associated with financial advisory fees in connection with the Company&#8217;s current capital raising efforts, as well as incremental costs associated with operating as a new public company. </FONT></P>
<P id=PARA28 style="TEXT-ALIGN: justify; MARGIN: 0pt 5.4pt 0pt 5pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA29 style="TEXT-ALIGN: justify; MARGIN: 0pt 5.4pt 0pt 5pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Net loss was $3.8 million, or $0.04 per share, for the three months ended June 30, 2016, compared to a net loss of $1.3 million, or $0.06 per share, for the three months ended June 30, 2015. The increase in the net loss was due primarily to higher expenses associated with the increased research and development expenses and general and administrative expenses.</FONT></P>
<P id=PARA30 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA31 style="TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 6.25pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>About Diffusion Pharmaceuticals Inc.</B></FONT></P>
<P id=PARA32 style="TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 6.25pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>&nbsp;</B></FONT></P>
<P id=PARA33 style="TEXT-ALIGN: justify; MARGIN: 0pt 6.65pt 0pt 6pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.2pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Diffusion Pharmaceuticals Inc. is a clinical stage biotechnology company focused on extending the life expectancy of cancer patients by improving the effectiveness of current standard-of-care treatments including radiation therapy and chemotherapy. Diffusion is developing its lead drug, <I>trans sodium crocetinate </I>(TSC), for use in the many cancer types in which tumor hypoxia (oxygen deprivation) is known to diminish the effectiveness of current treatments. TSC targets the cancer&#39;s hypoxic micro-environment, re-oxygenating treatment-resistant tissue and making the cancer cells more vulnerable to the therapeutic effects of treatments such as radiation therapy and chemotherapy, without the apparent addition of any serious side effects.</FONT></P>
<P id=PARA34 style="TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA35 style="TEXT-ALIGN: justify; MARGIN: 0pt 6.2pt 0pt 6.25pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.2pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">A Phase 2 clinical program, completed in the second quarter of 2015, evaluated 59 patients with newly diagnosed glioblastoma multiforme (GBM). This open label, historically controlled study demonstrated a favorable safety and efficacy profile for TSC combined with standard of care. The U.S. Food and Drug Administration has agreed upon the design of a Phase 3 trial in newly diagnosed GBM. Additional planned studies include a Phase 2 trial in pancreatic cancer and a study in brain metastases. Due to its novel mechanism of action, TSC has safely re-oxygenated a range of tumor types in our preclinical and clinical studies. Diffusion believes its therapeutic potential is not limited to specific tumors, thereby making it potentially useful to improve standard- of-care treatments of other life-threatening cancers. We also believe that TSC has potential application in other indications involving hypoxia, such as stroke and neurodegenerative diseases.</FONT></P>
<P id=PARA37 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA36 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 8pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Forward-Looking Statements</B></FONT></P>
<P id=PARA39 style="MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA38 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 8pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><I>To the extent any statements made in this news release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the company&#39;s plans, objectives, expectations&nbsp; and intentions with respect to future operations and products, the potential of the combined company&#39;s technology and product candidates, the anticipated timing of future clinical trials, the anticipated financial position, operating results and growth prospects of the combined company and other statements that are not historical in nature, particularly those that utilize terminology such as "would," "will," "plans," "possibility," "potential," "future," "expects," "anticipates," "believes," "intends," "continue," "expects," other words of similar meaning, derivations of such words and the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause the company&#39;s actual results to be materially different than those expressed in or implied by such forward-looking statements. Particular uncertainties and risks include; general business and economic conditions; the company&#39;s need for and ability to obtain additional financing; and the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance. All forward-looking statements in this news release speak only as of the date of this news release and are based on management&#39;s current beliefs and expectations. Diffusion undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.</I></FONT></P>
<P id=PARA56.1 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT></P>
<DIV id=PGBK56  style="WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<DIV id=PGFTR56  style="WIDTH: 100%; TEXT-ALIGN: center">&nbsp;</DIV>
<DIV id=PGNUM56  style="FONT-SIZE: 10pt; WIDTH: 100%; TEXT-ALIGN: center">&nbsp;</DIV>
<HR style="HEIGHT: 2px; WIDTH: 100%; PAGE-BREAK-AFTER: always; COLOR: #000000" noShade>

<DIV id=PGHDR56  style="WIDTH: 100%; TEXT-ALIGN: left">&nbsp;</DIV></DIV>
<P id=PARA56.2 style="MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</FONT><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA40 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 8pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>Diffusion Pharmaceuticals Contacts</B></FONT></P>
<P id=PARA42 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><B>&nbsp;</B></FONT></P>
<P id=PARA43 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 8pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">David Kalergis</FONT></P>
<P id=PARA44 style="TEXT-ALIGN: left; MARGIN: 0pt 67.6% 0pt 8pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.2pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Chief Executive Officer Diffusion Pharmaceuticals Inc. (434) 220-0718</FONT></P>
<P id=PARA45 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 8.25pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">dkalergis@diffusionpharma.com</FONT></P>
<P id=PARA46 style="TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</FONT></P>
<P id=PARA47 style="TEXT-ALIGN: left; MARGIN: 0pt 75.3% 0pt 8pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 0.45pt"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Stephanie Carrington ICR Inc.</FONT></P>
<P id=PARA48 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 8.25pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">(646) 277-1282</FONT></P>
<P id=PARA49 style="TEXT-ALIGN: left; MARGIN: 0pt 0pt 0pt 8.5pt; LINE-HEIGHT: 1.25"><FONT style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Stephanie.Carrington@icrinc.com</FONT></P></BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>a2.jpg
<TEXT>
begin 644 a2.jpg
M_]C_X  02D9)1@ ! 0$ E@"7  #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@                  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
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M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
MGJZ?'9^+G_J@::#8H4>AMJ(FHI:C!J-VH^:D5J3'I3BEJ:8:IHNF_:=NI^"H
M4JC$J3>IJ:H<JH^K JMUJ^FL7*S0K42MN*XMKJ&O%J^+L "P=;#JL6"QUK)+
MLL*S.+.NM"6TG+43M8JV ;9YMO"W:+?@N%FXT;E*N<*Z.[JUNRZ[I[PAO)N]
M%;V/O@J^A+[_OWJ_]<!PP.S!9\'CPE_"V\-8P]3$4<3.Q4O%R,9&QL/'0<>_
MR#W(O,DZR;G*.,JWRS;+MLPUS+7--<VUSC;.ML\WS[C0.="ZT3S1OM(_TL'3
M1-/&U$G4R]5.U='65=;8UUS7X-ADV.C9;-GQVG;:^]N W 7<BMT0W9;>'-ZB
MWRG?K^ VX+WA1.',XE/BV^-CX^OD<^3\Y83F#>:6YQ_GJ>@RZ+SI1NG0ZEOJ
MY>MPZ_OLANT1[9SN*.ZT[T#OS/!8\.7Q<O'_\HSS&?.G]#3TPO50]=[V;?;[
M]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^W/]M____X  2 !!*1DE&  $"
M  3[!GX  /_; $,  @$! @$! @(" @(" @(#!0,# P,#!@0$ P4'!@<'!P8'
M!P@)"PD(" H(!P<*#0H*"PP,# P'"0X/#0P."PP,#/_; $,! @(" P,#!@,#
M!@P(!P@,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,#/_  !$( #T 9 ,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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MK2]2\511ZI9R2Q36:Z?=RW"O'J,.FLHC2(L6-Y<0QJ "7$@==T>7$-C^W?\
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..)9B%099B23R310!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>a1.jpg
<TEXT>
begin 644 a1.jpg
M_]C_X  02D9)1@ ! 0$ WP#>  #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@                  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
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M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
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M# P,# P,# P,#/_  !$( "X E@,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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M=GYV2J&YNKB*-(X@X^<)ODP.$.17OO[37_!%_P#9K_;#^+FJ>//B)\.?[?\
M%VL10P7>HKK^J6;R+%$L4>$@N4C7:BJ,JH)QDY/-<]\.O^"!_P"R!\+O$$6J
M:;\%?#E]=VHP!KE_?:Y;YR""T%Y/+$3D#DIG!(Z$Y /R_P#^#:K]B[QM^TE^
MV_J7[4?C*&^&@^'9M3O+/59X?*7Q'KM^LT4[1#&'BB2XNB[+\JRO$HR5<)P/
M[9IQ_P '4=A_V5WP4?\ QW2?\:_HVT/0;3PWI5M8V%O;V=C9PI;VUO!$L4-O
M$H"JB(H"JH       %?//B__ ()%?L]^/OVIH_C7K'P^6\^)T.L66OKK9UO4
MHR+VT\K[/+Y"W @^001#;Y>P[>5.3D _+G_@\,&/C#\ 3C_F#Z[_ .CM/K]"
M_@:<_P#!O/X/_P"S=K+_ -1I*]5_;&_X)F?!']O[6/#^H?%OP2OBV[\+PSV^
MF2?VO?V/V6.<QM*N+6>(-N,49^?=C;QCFO0M&_9X\(^'OV=K/X46>D^3X"L/
M#J>$X-+%U.VS3$MA:K;^<7,QQ  F\N7[[MW- 'XC?\&>?/[07QG_ .Q8TL_^
M3,X_I7C7_!P_HUQ\!O\ @MQ<^-+RWN+RSUBW\.>+;:-5"F:*V2.U>.-C\I.Z
MP?DG@OS@8K]UOV.?^"8'P-_8#\0ZUJOPE\#KX3O_ !%;1V>H2C6-0OO/AC9G
M1,7,\H7#,Q^4 \UJ?MI?\$]OA%_P4%\&Z?HOQ7\)6_B*'19)9M+NX[F:ROM,
M>10LGDW$#I(JMM0LFXHYCC+*Q1< 'XZ?\'%W_!7KX*_M[?LT?#OP'\*=<U#Q
M5>6?B6/Q;J5U_9ES9P:9%%975JD$GVB-&:5WO@?D#*ODD,<LH;ZM_P""<'Q
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M_#7_ (-U_P!C_P"&?C2/7;?X71ZU/;W'VBWM-=UR_P!6L(FRQVM;3S-%,N&
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M%B+X_:M#-8ZJCZ=H"Z;!#8_9Y+D)#;[<[972-RSDJ2XC?/0,/KKX0? +P?\
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M\-Z+J-C(R2R0ZC]BD:X60-;/%$T,3.+@@LI3YN0L/^"V=]XE_9[^'7BKP_\
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MDQ>*[_2+BRL?M[:=K$4=O&+65K<2D31-+#YEM-'G/E-+[!9_\%"-3UO]G/\
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+<'(![%1110!__]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
